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The human cytomegalovirus (HCMV) major immediate-early enhancer has been postulated to play a pivotal
role in the control of latency and reactivation. However, the absence of an animal model has obstructed a direct
test of this hypothesis. Here we report on the establishment of an in vivo, experimentally tractable system for
quantitatively investigating physiological functions of the HCMV enhancer. Using a neonate BALB/c mouse
model, we show that a chimeric murine CMV under the control of the HCMV enhancer is competent in vivo,
replicating in key organs of mice with acute CMV infection and exhibiting latency/reactivation features
comparable for the most part to those of the parental and revertant viruses.
Reactivation of human cytomegalovirus (HCMV) in an im-
munocompromised host frequently leads to a variety of severe
complications, such as pneumonia, hepatitis, and retinitis (30).
The HCMV major immediate-early promoter (MIEP) has
been regarded as a key genetic element in determining the
commencement of lytic infection and the switch from latency
to reactivation (17, 35, 36). The MIEP steers the extent and
patterns of expression of the MIE genes, which encode multi-
functional proteins required for the productive replication cy-
cle (25, 28). The enhancer region of the MIEP is controlled by
a complex interplay between host factors and virally encoded
proteins (12, 36). Thus, binding sites for multiple signal-regu-
lated cellular factors, such as NF-B, CREB/ATF, Sp1, AP-1,
YY1, Ets, RAR/RXR, and serum response factors, lie in this
regulatory region. The importance of the HCMV MIEP en-
hancer in the context of the infection of cultured cells has been
documented (15, 18, 20, 26, 27). However, the lack of an
animal model system that sustains significant HCMV replica-
tion has prevented the assessment of the role and mechanisms
of action of this region during latent infection. Thus, there is an
urgent need to develop in vivo models to address this issue.
Infection of mice with murine CMV (MCMV) has proven to
be an invaluable model for studying aspects of the biology of
CMV infection. The MCMV MIE locus resembles in many
ways its HCMV counterpart, and significant information has
been drawn from this system concerning MIE gene functions
and MIEP regulation (8, 33). In this context, we have described
the absolute requirement of the MCMV enhancer for produc-
tive infection in its natural host (13). While the primary se-
quence and architecture of the MCMV and HCMV enhancers
are quite different, they share many of the same signal-regu-
latory control elements (7, 10, 12), conferring both similar and
distinct biological properties to them. Accordingly, the first
attempts to study HCMV MIEP function in an intact physio-
logical system involved developing murine transgenic models
using an HCMV enhancer linked to a reporter gene (3, 4, 23).
However, while informative, these models place the enhancer
out of its natural environment of the viral genome and most
importantly out of the context of an infection. For these rea-
sons, we sought to address HCMV-enhancer-related questions
during viral infection in an in vivo setting by generating the first
chimeric humanized MCMV (hMCMV) in which the HCMV
enhancer precisely replaces the MCMV enhancer (2). We
showed that this enhancer swap virus replicated in permissive
NIH 3T3 cells with wild-type kinetics. These observations were
extended by Grzimek et al. (14), who used an independent
hybrid virus (mCMVhMIEPE) in which the complete MCMV
promoter was replaced by both the enhancer and the core
promoter of HCMV; this recombinant virus showed normal
growth in liver but a partial defect in dissemination or repli-
cation within other tissues in immunodepleted BALB/c mice.
However, these two enhancer swap viruses were generated on
the basis of MCMV genomes lacking one or more viral immu-
nomodulatory genes, which thus led to an attenuated pheno-
type of the resulting viruses in vivo (24, 37). This deficiency
made the quantitative study of the acute infection difficult and
greatly impeded the possibility of investigating latency and
reactivation issues.
In this report, we have sought to establish a robust in vivo
model for studying HCMV enhancer functions in the context
of an acute and latent infection. For this purpose, we used a
new chimeric virus (hMCMV-ES, where ES signifies enhancer
swap [5]) engineered from a full-length MCMV-bacterial arti-
ficial chromosome (BAC) genome (37) through recombination
techniques in Escherichia coli (6). In this recombinant virus,
sequences from nucleotides 48 to 1191 of the native
MCMV enhancer were replaced by the paralogous sequence
from nucleotides 52 to 667 of the HCMV enhancer (Fig.
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FIG. 1. Genetic organization and in vitro growth analysis of parental MCMV, hMCMV-ES, and hMCMV-ESrev. (A) Schematic illustrations
of the parental MCMV, hMCMV-ES, and hMCMV-ESrev genomes. The top line represents the HindIII map of the parental MCMV genome (11),
with the HindIII K and L regions enlarged below to show the MIE locus and with the structure of the MIE transcripts (ie1, ie2, and ie3) indicated.
Exons of the ie1-ie3 transcription unit are depicted as gray rectangles. The hatched box represents the MCMV enhancer. Line 1 represents the
HindIII fragments K and L from parental MCMV (obtained from the pSM3fr BAC [37]). The hMCMV-ES genome (line 2) was generated by
homologous recombination in E. coli (6), with the MCMV pSM3fr BAC taken as the parental genome and with MCMV enhancer sequences from
nucleotides 48 to 1191 (relative to the ie1/ie3 MCMV transcription start site) replaced by sequences from nucleotides 52 to 667 (relative
to the ie1/ie2 HCMV transcription start site) of the HCMV enhancer (represented by a black box). In the hMCMV-ESrev genome (line 3), the
native sequences of the MCMV enhancer were reintroduced in hMCMV-ES by replacement of the HCMV enhancer. Sizes of the natural and new
HindIII L DNA fragments for each recombinant genome are indicated. The illustration is not drawn to scale. (B) Growth kinetics of hMCMV-ES
and control viruses in different cell types. NIH 3T3 cells, MEF, SVEC-4 cells, MMH cells (treated for 10 days before infection with 2% dimethyl
sulfoxide), and C127I cells were infected at an MOI of 0.025 PFU/cell, and RAW264.7 cells were infected at an MOI of 0.1 PFU/cell, with MCMV,
hMCMV-ES, or hMCMV-ESrev. At the designated days p.i., cell supernatants were collected and titrated by standard plaque assays on MEF.
Error bars represent standard deviations of the means of results from triplicate cultures. Asterisks denote statistically significant differences
between hMCMV-ES-, MCMV-, or hMCMV-ESrev-infected samples (P value  0.05) determined by Student’s t test (two-tailed).
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1A, lines 1 and 2). As a control, we generated a revertant
genome by restoring the MCMV enhancer in hMCMV-ES
(hMCMV-ESrev) (Fig. 1A, line 3), transfected hMCMV-
ESrev into NIH 3T3 cells, recovered the corresponding virus,
and subjected it to three rounds of plaque purification, and a
viral stock was produced. The genomic integrity of the three
viruses used in the study was verified by HindIII digestion of
the viral DNAs (see Fig. S1 in the supplemental material).
Further characterization of the recombinant MCMVs was per-
formed by DNA digestion with additional restriction enzymes,
PCR analysis, and sequencing across the MIE region manipu-
lated (data not shown). Finally, viral stocks were tested by PCR
for the appropriate excision of the BAC vector sequences (see
Fig. S2 in the supplemental material), as any remaining BAC
sequences in the viral genome could interfere with the natural
course of the infection in mice.
We first sought to analyze the growth phenotype of
hMCMV-ES in different murine cell types in culture. For this
purpose, we infected NIH 3T3 cells, mouse embryo fibroblasts
(MEF), an endothelial cell line (SVEC-4), a liver-derived cell
line (MMH [1]), an epithelial cell line (C127I), and the mac-
rophagic cell line RAW264.7 with parental MCMV, hMCMV-
ES, and hMCMV-ESrev at a low multiplicity of infection
(MOI). Figure 1B shows that while no significant growth de-
fects were detected with hMCMV-ES in the first three cell
types, a slightly diminished ability (around 1 order of magni-
tude) to replicate in MMH, C127I, and RAW264.7 cells was
exhibited by this recombinant virus. As expected, the revertant
virus was identical to the parental virus in growth kinetics in
these cell systems. Thus, although the HCMV enhancer was
able to complement the native MCMV enhancer in a variety of
cultured cells, these data highlight the distinct cell-specific
regulation of viral growth by this region.
We next proceeded to analyze whether differential sensitiv-
ity also exists in the in vivo phenotype of hMCMV-ES in the
immunocompetent-BALB/c-mouse model. Groups of 3-week-
old mice were infected intraperitoneally (i.p.) with 1  106
PFU of hMCMV-ES or the parental or revertant viruses. At 4,
7, and 14 days postinfection (p.i.), viral titers were examined in
relevant sites of MCMV replication. As shown in Fig. 2,
hMCMV-ES was able to infect and propagate in the spleen,
liver, kidneys, lungs, and salivary glands, although it was con-
siderably attenuated (1 to 2 orders of magnitude, depending on
the organ) in comparison to the parental and revertant viruses.
Similar results were obtained in immunodeficient SCID CB17
mice (data not shown). These data are, overall, consistent with
previous observations made with the slightly different hybrid
virus mCMVhMIEPE in immunodepleted adult BALB/c mice
(14). Altogether, the difference in sensitivity appears to be a
general, quantitative attenuation in vivo that was observed for
all tissues rather than being specific to a cell/organ system.
The diminished growth of hMCMV-ES in different tissues
during acute infection severely impairs the study of the HCMV
enhancer in this system. To overcome this limitation, we ini-
tially attempted to infect adult BALB/c mice with higher doses
of hMCMV-ES. Although this level of inoculation permitted
more-vigorous replication in the different organs tested (data
not shown), it generated technical problems associated with
the production of highly concentrated viral stocks. In a search
of a more sensitive model of infection, we turned to neonatal
mice. Work by Reddehase and colleagues (32) has shown that
intraperitoneal infection of neonatal BALB/c mice with low
doses of MCMV (1  102 PFU) leads to significant virus
production in different organs and subsequent establishment
of latency. Accordingly, we first analyzed the degree of viru-
lence of hMCMV-ES in comparison to that of the parental
virus in this system. For this purpose, we challenged groups of
3-day-old BALB/c mice with various doses of hMCMV-ES
(ranging from 1  103 to 2  106 PFU/mouse) or parental and
revertant viruses (ranging from 1  102 to 1  104 PFU/
mouse) and evaluated their survival daily for at least a 40-day
period. As shown in Fig. 3A, while the estimated 50% lethal
dose (LD50) for control viruses was 1.3  10
3 (parental) and
1.4 103 (revertant) PFU, the LD50 for hMCMV-ES was 2
orders of magnitude higher, 1.7  105 PFU, reflecting the
significant decrease in virulence associated with hMCMV-ES.
Based on the LD50 values determined, and in order to es-
tablish conditions that allowed a robust hMCMV-ES infection
comparable to that of wild-type MCMV, we proceeded to
inoculate 3-day-old BALB/c mice with a viral dose correspond-
ing to 0.3 LD50 (5  10
2 PFU/mouse for control viruses and
FIG. 2. Growth of hMCMV-ES, parental, and revertant viruses in
adult BALB/c mice. Three-week-old BALB/c.ByJ female mice were
inoculated i.p. with 1  106 PFU per mouse of tissue culture-derived
MCMV, hMCMV-ES, or hMCMV-ESrev. Animals were sacrificed at
the different times p.i. indicated, selected organs were harvested and
sonicated as a 10% (wt/vol) tissue homogenate, and titers were deter-
mined by standard plaque assays, including centrifugal enhancement
of infectivity (16) on MEF. The dashed line indicates the limit of
detection (3 101 PFU/g). Horizontal bars indicate the median values.
Viral titers in the different organs and times shown were significantly
different (P value  0.05) between groups of animals infected with
hMCMV-ES and the parental virus as determined by the Mann-Whit-
ney test (two-tailed).
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5  104 PFU/mouse for hMCMV-ES). We then evaluated the
growth of hMCMV-ES in comparison to that of the control
viruses in the major target organs for CMV at different days
p.i. Under these conditions, hMCMV-ES grew to levels equiv-
alent to and followed a course similar to those of the parental
and revertant viruses in spleen, liver, lungs, kidneys, and sali-
vary glands at days 4 and 7 after infection (Fig. 3B). Reduced
viral yields (compared to those from mice infected with the
corresponding controls) were found only in the salivary glands
of hMCMV-ES-infected animals 14 days after inoculation. Di-
FIG. 3. Infection of neonate BALB/c mice with hMCMV-ES. (A) Virulence level of hMCMV-ES in newborn mice. Groups of 7 to 34 3-day-old
BALB/c.ByJ female mice were i.p. inoculated with increasing doses of tissue culture-derived hMCMV-ES (ranging from 1  103 to 2  106 PFU
per mouse) or parental or revertant viruses (ranging from 1  102 to 1  104 PFU per mouse). Animals were monitored daily for survival until
at least 40 days postinoculation. Data points were fitted to a sigmoid function available in Origin software, and the LD50 values were estimated
from these curves. (B) Growth kinetics of hMCMV-ES in newborn mice. Three-day-old BALB/c.ByJ female mice were i.p. inoculated with tissue
culture-derived hMCMV-ES (5  104 PFU per mouse), MCMV, or hMCMV-ESrev (5  102 PFU per mouse). Mice were sacrificed at different
times after infection and specific organs removed. Collected organs were sonicated as a 10% (wt/vol) tissue homogenate, and titers were
determined by standard plaque assays, including centrifugal enhancement of infectivity on MEF. All values were among the limits of detection of
the assay (5  101 PFU). Horizontal bars indicate the median values. The observed differences did not reach statistical difference (P value  0.05)
as determined by the Mann-Whitney test (two-tailed), except for the values for salivary glands at day 14 p.i., with which a significant difference was
obtained between the group of animals infected with hMCMV-ES and the group infected with MCMV or hMCMV-ESrev. (C) Histological
analysis of livers and spleens from MCMV- and hMCMV-ES-infected newborn mice. Portions of the spleens and livers removed at day 7 p.i. from
animals discussed for panel B above were fixed in 4% formaldehyde, processed, and embedded in paraffin by standard procedures. Sections (3 to
4 m) were cut with a rotary microtome and stained with hematoxylin and eosin for examination. Shown are sections from spleens of
MCMV-infected animals (subpanel A) and hMCMV-ES-infected animals (subpanel B), with regions exhibiting mild lymphoid depletion in the
white pulp enclosed by dashed lines. These lesions were frequently associated with discrete inflammatory aggregates mostly constituted by
macrophagic cells and occasionally accompanied by eosinophilic intranuclear inclusion bodies. (Subpanels C to E) Liver sections of MCMV-
infected mice (subpanel C) and hMCMV-ES-infected mice (subpanels D and E), where moderate inflammatory lesions dispersed through the
parenchymata can be recognized (enclosed by dashed lines). Scattered necrotic hepatocytes, cytomegalic cells (red arrow in subpanel D), and
Cowdry type A intranuclear inclusions bodies (inset subpanel E and black arrow in subpanel D) could be distinguished in these inflammatory foci.
The bars represent 100 m in panels A to B, 50 m in panels C to D, and 20 m in panel E.
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rect inoculation of the chimeric virus in the submaxillar gland
did not ameliorate this partially impaired growth (data not
shown), thus suggesting a particular defect of hMCMV-ES in
replicating in this gland more than an incapacity of the mutant
virus to successfully reach it. Therefore, except in the salivary
glands, conditions were established in the neonatal murine
model that allowed hMCMV-ES to disseminate and replicate
in relevant organs involved in acute infection. In agreement
with the viral titers obtained, signs of MCMV-associated pa-
thology were observed in the different organs analyzed from
hMCMV-ES-infected animals and were more prominent in
spleens and livers than in other organs. Figure 3C shows some
of the lesions observed in these two organs. While, quantita-
tively, lesions in the spleens of hMCMV-ES- and MCMV-
infected mice were very similar, slightly more frequent and
florid lesions were observed in the livers of animals inoculated
with the virus with the replaced enhancer.
We next examined whether, under these experimental con-
ditions, hMCMV-ES was capable of establishing latency and
subsequently reactivating from this state. Groups of 9 to 12
3-day-old mice were infected with 5  104 PFU of
hMCMV-ES or 5  102 PFU of the parental virus. After 4
months, when persistent virus could no longer be detected in
salivary gland homogenates, viral reactivation was investigated
with splenic and lung explants as described by Jordan and Mar
(21) and Presti et al. (31), systems that have proven to be more
efficient and reproducible than in vivo reactivation techniques.
As shown in Fig. 4, reactivation in spleens was detected in 78%
of animals infected with the parental virus and in 67% of
animals infected with hMCMV-ES. The frequency of reactiva-
tion of hMCMV-ES in the lungs, although lower than in
spleens, was also similar to that exhibited by the parental virus
(50% and 33% for the mutant and the parental virus, respec-
tively). In addition, in both organs, the reactivation of the two
viruses followed roughly similar kinetics. Thus, under the ex-
perimental conditions established, the efficiency and dynamics
of reactivation of hMCMV-ES in explant cultures were com-
parable to those of the parental virus.
The exchange between enhancers of different CMV species
results in hybrid viruses with similar or slightly diminished in
vitro replication abilities but significantly altered dissemination
capacities and/or host cell tropisms (2, 14, 18, 34). These ob-
servations highlight the biological significance of this regula-
tory region, most likely adapted during coevolution to suit
species-specific niches. In order to develop a system that allows
the study of the HCMV enhancer in the different settings in
vivo, we have used here the hMCMV-ES virus and the neonate
mouse model and established conditions of infection that
mostly reproduce the extent of viral replication in different
organs and parallel latency/reactivation properties of parental
MCMV. Until now, the study of particular genetic elements of
the HCMV enhancer in the context of the complete viral
genome has been restricted to a few tissue culture systems (5,
9, 15, 19, 22, 29). Thus, for the first time, it is possible to
FIG. 4. Reactivation of hMCMV-ES virus. Groups of 9 to 12 3-day-old BALB/c.ByJ female mice were i.p. inoculated with tissue
culture-propagated hMCMV-ES (5  104 PFU per mouse) or the parental virus (5  102 PFU per mouse) and maintained for 4 months to
establish latency. Animals were sacrificed and their spleens, lungs, and salivary glands harvested. Reactivation was examined from spleens
and lungs, which were manually minced and placed with medium in wells of a six-well plate. Cultures were kept (with fresh medium addition
when required) for 50 days. Every 5 days, part of the supernatant was transferred to MEF monolayers (a centrifugal enhancement of
infectivity step was included) for detection of infectious virus. Graphics show the cumulative frequencies of reactivation events over time
from spleen (A) and lung (B) explants. The percentages of reactivation accumulated at day 50 postexplantation are indicated in the
corresponding tables, with the number of positive mice versus the number of total animals per group shown in parentheses. The identities
of the reactivated viruses (which differ within groups in the sizes of the HCMV and MCMV enhancer regions) were confirmed by PCR
analysis using two primers that bind to viral sequences flanking the MCMV enhancer and as template viral DNAs from the indicator MEF
cultures when a cytopathic effect was reached (data not shown). In addition, PCR products from a representative sample of each group and
organ were cloned and sequenced. Salivary glands were analyzed to ensure the clearance of infectious virus at the time of explantation by
sonicating them as a 10% (wt/vol) tissue homogenate and subsequently transferring them to MEF monolayers. Data shown correspond to
results from one of two independently performed experiments in which comparable results were obtained. Percentages of reactivation
between MCMV and hMCMV-ES were not statistically different, as determined by the chi-square test (two-tailed).
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ascertain the roles of selective HCMV enhancer binding ele-
ments, cellular factors, and signaling pathways operating
through this region in an intact physiological system, in the
establishment and maintenance of latency, and in the control
of the reactivation events in the context of an in vivo infection.
Knowledge of the mechanisms governing enhancer function
may lead to new strategies for controlling primary and recur-
rent HCMV infections, with the small-animal model system
established here being a valuable tool for their evaluation.
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